Last reviewed · How we verify

NCT05321199

Tranexamic Acid During Telescoping Nail Application In Osteogenesis Imperfecta

Completed NA Last updated 14 December 2023
What this trial tests

NA trial testing Tranexamic acid in Osteogenesis Imperfecta in 20 participants. Completed in 30 November 2023.

Timeline
1 May 2022
Primary endpoint
30 November 2023
30 November 2023

Quick facts

Lead sponsorAssiut University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designsequential
Maskingnone
Primary purposescreening
Enrollment20
Start date1 May 2022
Primary completion30 November 2023
Estimated completion30 November 2023
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Eligibility, any sex, with Osteogenesis Imperfecta. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to assess the effective of intraoperative use of tranexamic acid in reducing blood loss during telescoping nail application in cases of osteogenesis imperfecta.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Tranexamic acid

Trials testing the same drug.

Other recruiting trials for Osteogenesis Imperfecta

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05321199.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing